CD133+ cancer stem cells in lung cancer

Frontiers in Bioscience

Volumn 18, Issue 2, 2013, Pages 447-453

  Wang, Shuang ^a   Xu, Zhen Ye ^a   Wang, Li Fang ^a   Su, Wan ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cancer Stem Cell; Hematopoietic Stem; Non Small Cell Lung Cancer; Progenitor Cells; Review

Indexed keywords

CD133 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MICRORNA; MIRN145 MICRORNA, HUMAN; OCTAMER TRANSCRIPTION FACTOR 4; PEPTIDE; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; CANCER STEM CELL; CELL TRANSFORMATION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG TUMOR; METASTASIS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS;

ADENOCARCINOMA; ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MICRORNAS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PEPTIDES; PROGNOSIS; SMALL CELL LUNG CARCINOMA; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84878803940     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4113     Document Type: Article

References (60)

1. Minna JD, Roth JA, Gazdar AF: Focus on lung cancer. Cancer Cell 1, 49-52. (2002) (Pubitemid 41039175)
2. Giangreco A, Groot KR, Janes SM: Lung cancer and lung stem cells: strange bedfellows? Am J Respir Crit Care Med 175, 547-553 (2007) (Pubitemid 46438936)
3. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, CA Cancer J Clin 52, 23-47 (2002)
4. Giangreco A, Groot KR, Janes SM: Lung cancer and lung stem cells: strange bedfellows? Am J Respir Crit Care Med 175, 547-53 (2007) (Pubitemid 46438936)
5. Ho MM, Ng AV, Lam S, Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67, 4827-33 (2007) (Pubitemid 46910191)
6. Yin AH, Miraglia S, Zanjani ED: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90, 5002-12. (1997) (Pubitemid 28007217)
7. Miraglia S, GodfreyW, YinAH: A novel fivetransmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90, 5013-21 (1997) (Pubitemid 28007218)
8. Uchida N, Buck DW, He D: Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 97, 14720-14725 (2000) (Pubitemid 32016642)
9. Salven P, Mustjoki S, Alitalo R: VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 101, 168-172 (2003) (Pubitemid 36025904)
10. Richardson GD, Robson CN, Lang SH: CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117:3539-3545 (2004) (Pubitemid 39206394)
11. Piechaczek C: CD133. J Biol Regul Homeost Agents 15,101-102 (2001) (Pubitemid 32492736)
12. Zhu L, Gibson P, Currle DS: Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457, 603-7 (2009)
13. Singh SK, Hawkins C, Clarke ID: Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004) (Pubitemid 39551674)
14. Maitland NJ, Collins AT: Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26, 2862-70 (2008)
15. Hermann PC, Huber SL, Herrler T: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313- 23 (2007) (Pubitemid 47355323)
16. Jaksch M, Munera J, Bajpai R: Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, andmelanoma cell lines. Cancer Res 68, 7882-6 (2008)
17. Kim M, Koh YJ, Kim KE: CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res 70, 10411-21 (2010)
18. Ricci-Vitiani L, Lombardi DG, Pilozzi E: Identification and expansion of human colon-cancer-initiating cells. Nature 445:111-5 (2007) (Pubitemid 46067311)
19. O'Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-10 (2007) (Pubitemid 46067310)
20. Shimada M, Sugimoto K, Iwahashi S: CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 45, 896-902 (2010)
21. Ma S, Chan KW, Lee TK: Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 6, 1146-53 (2008)
22. Stewart JM, Shaw PA, Gedye C: Phenotypic heterogeneity and instability of human ovarian tumorinitiating cells. Proc Natl Acad Sci U S A 108, 6468-73 (2011)
23. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ: Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 71(11), 3991-4001 (2011)
24. Wang J, Sakariassen PØ, Tsinkalovsky O: CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122, 761-768 (2008)
25. Ogden AT, Waziri AE, Lochhead RA: Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 62, 505-514 (2008) (Pubitemid 351489297)
26. Shmelkov SV, Butler JM, Hooper AT: CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 20118, 2111-2120 (2008) (Pubitemid 351872330)
27. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15(3), 504-14 (2008) (Pubitemid 351267301)
28. Bertolini G, Roz L, Perego P: Highly tumorigenic lung cancer CD133+ cells display stemlike features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106, 16281-6 (2009)
29. Liu D, Li WM, Mo XM, Liu LX, Wang Y, Che GW, Wu Z, Gou JL: Multiparametric flow cytometry analyzes the expressions of immunophenotype CD133, CD34, CD44 in lung cancer naive cells. Sichuan Da Xue Xue Bao Yi Xue Ban 39(5), 827-31 (2008)
30. Moreira AL, Gonen M, Rekhtman N, Downey RJ: Progenitor stem cell marker expression by pulmonary carcinomas. Mod Pathol 23(6), 889-95 (2010)
31. Wang B, Yang H, Huang YZ, Yan RH, Liu FJ, Zhang JN: Biologic characteristics of the side population of human small cell lung cancer cell line H446. Chin J Cancer 29(3), 254-60 (2010)
32. Cui F, Wang J, Chen D, Chen YJ: CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Oncol Rep 25(3), 701-8 (2011)
33. Peng Q, Liu M, Song SM, Li XH, Du YH, Zhi Y, Wang MY: The recruitment of exogenous endothelial progenitor cells in lung tumor model of nude mice. Chin J Cancer 29(11), 952-8 (2010)
34. Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, Pirozzi G: The role of CD133 in the identification and characterisation of tumourinitiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 36(3), 446-53 (2009)
35. Janikova M, Skarda J, Dziechciarkova M, Radova L, Chmelova J, Krejci V, Sedlakova E, Zapletalova J, Langova K, Klein J, Grygarkova I, Kolek V: Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154(4), 321-6 (2010)
36. Zhang HZ, Lin XG, Hua P, Wang M, Ao X, Xiong LH, Wu C, Guo JJ: The study of the tumor stem cell properties of CD133+CD44+ cells in the human lung adenocarcinoma cell line A549. Cell Mol Biol (Noisy-le-grand) 56 Suppl, OL1350-8 (2010)
37. Jiang T, Collins BJ, Jin N, Watkins DN, Brock MV, Matsui W, Nelkin BD, Ball DW: Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. Cancer Res 69(3), 845-54. (2009)
38. Hsu HS, Huang PI, Chang YL, Tzao C, Chen YW, Shih HC, Hung SC, Chen YC, Tseng LM, Chiou SH: Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 117(13), 2970-85 (2011)
39. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, Saijo N, Nishio K: mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 69(18), 7160-4 (2009)
40. Zhou X, Chen H, Wang Q, Zhang L, Zhao J: Knockdown of Mgat5 inhibits CD133+ human pulmonary adenocarcinoma cell growth in vitro and in vivo. Clin Invest Med 34(3), E155- 62 (2011)
41. Iida H, Suzuki M, Goitsuka R, Ueno H: Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol. 2012;40(1):71-9. ()
42. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3(7), e2637 (2008)
43. Zhang S, Wu Y, Feng D, Zhang Z, Jiang F, Yin R, Xu L: miR-145 inhibits lung adenocarcinoma stem cells proliferation by targeting OCT4 gene. Zhongguo Fei Ai Za Zhi 14(4), 317- 22 (2011)
44. Yin R, Zhang S, Wu Y, Fan X, Jiang F, Zhang Z, Feng D, Guo X, Xu L: microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. Oncol Rep 25(6), 1747-54 (2011)
45. Chiou GY, Cherng JY, Hsu HS, Wang ML, Tsai CM, Lu KH, Chien Y, Hung SC, Chen YW, Wong CI, Tseng LM, Huang PI, Yu CC, Hsu WH, Chiou SH: Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J Control Release (Epub ahead of print) (2012)
46. Li W, Jian-jun W, Xue-Feng Z, Feng Z: CD133(+) human pulmonary adenocarcinoma cells induce apoptosis of CD8(+) T cells by highly expressed galectin-3. Clin Invest Med 33 (1), E44-53 (2010)
47. Xu YH, Zhang GB, Wang JM, Hu HC: B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Med J 31 (9), 980-6 (2010)
48. Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, Yamamoto T, Rino Y, Kitamura H, Masuda M: Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 4 (1), 32-42 (2010)
49. Herpel E, Jensen K, Muley T, Warth A, Schnabel PA, Meister M, Herth FJ, Dienemann H, Thomas M, Gottschling S: The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer. Anticancer Res 31 (12), 4491-500 (2011)
50. Li F, Zeng H, Ying K: The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med Oncol 28 (4), 1458-62 (2011)
51. Zhang HZ, Wei YP, Wang M, Wu C, Yang YQ, Chen J, Cao YK: Association of CD133 and endothelinconverting enzyme expressions with prognosis of nonsmall cell lung carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 27 (5), 696-9 (2007)
52. Hsieh JL, Lu CS, Huang CL, Shieh GS, Su BH, Su YC, Lee CH, Chang MY, Wu CL, Shiau AL: Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell deattachment and reattachment. Cancer Lett 321(1), 36-44 Epub (2012)
53. Lin X, Liu S, Liu N, Yang X, Xu H, Wang E: Expression and Significance of Stem cell Markers CK19, Notch3, CD133, P75NTR, STRO-1 and ABCG2 in Pulmonary Squamous Carcinomas. Zhongguo Fei Ai Za Zhi 12 (4), 316-21 (2009)
54. Bartling B, Koch A, Simm A, Scheubel R, Silber RE, Santos AN: Insulin-like growth factor binding proteins-2 and -4 enhance the migration of human CD34-/CD133+ hematopoietic stem and progenitor cells. Int J Mol Med 25 (1), 89-96 (2010)
55. Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, Maki Y, Muraoka T, Tanaka N, Ueno T, Asano H, Tsukuda K, Yamane M, Oto T, Kiura K, Miyoshi S: Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung cancer. (Epub ahead of print) (2012)
56. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3 (8), e3077 (2008)
57. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I: CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 126 (4), 950-8 (2010)
58. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106 (38), 16281-6 (2009)
59. Vroling L, Lind JS, de Haas RR, Verheul HM, van Hinsbergh VW, Broxterman HJ, Smit EF: CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br J Cancer 102 (2), 268-75 (2010)
60. Yi H, Cho HJ, Cho SM, Jo K, Park JA, Lee SH, Chang BJ, Kim JS, Shin HC: Effect of 5-FU and MTX on the Expression of Drug-resistance Related Cancer Stem Cell Markers in Non-small Cell Lung cancer Cells. Korean J Physiol Pharmacol 16 (1), 11-6 (2012)